CN100526219C - 稀土金属化合物、其制造方法及其使用方法 - Google Patents
稀土金属化合物、其制造方法及其使用方法 Download PDFInfo
- Publication number
- CN100526219C CN100526219C CNB03824117XA CN03824117A CN100526219C CN 100526219 C CN100526219 C CN 100526219C CN B03824117X A CNB03824117X A CN B03824117XA CN 03824117 A CN03824117 A CN 03824117A CN 100526219 C CN100526219 C CN 100526219C
- Authority
- CN
- China
- Prior art keywords
- compound
- lanthanum
- rare earth
- solution
- phosphoric acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims abstract description 85
- 150000002909 rare earth metal compounds Chemical class 0.000 title abstract 2
- 239000002245 particle Substances 0.000 claims abstract description 34
- 229910052746 lanthanum Inorganic materials 0.000 claims abstract description 22
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000010452 phosphate Substances 0.000 claims abstract description 14
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 13
- 150000001875 compounds Chemical class 0.000 claims description 74
- 150000003016 phosphoric acids Chemical class 0.000 claims description 51
- -1 rare earth compound Chemical class 0.000 claims description 43
- 229910052761 rare earth metal Inorganic materials 0.000 claims description 39
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 30
- 238000002360 preparation method Methods 0.000 claims description 25
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 15
- 150000002910 rare earth metals Chemical class 0.000 claims description 14
- 238000001914 filtration Methods 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 5
- 230000000274 adsorptive effect Effects 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- 239000013049 sediment Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 34
- 238000004519 manufacturing process Methods 0.000 abstract description 16
- 239000012530 fluid Substances 0.000 abstract description 14
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract description 13
- 229910052751 metal Inorganic materials 0.000 abstract description 10
- 239000002184 metal Substances 0.000 abstract description 10
- 201000005991 hyperphosphatemia Diseases 0.000 abstract description 6
- 229910021645 metal ion Inorganic materials 0.000 abstract description 5
- 229910052684 Cerium Inorganic materials 0.000 abstract description 3
- 241000124008 Mammalia Species 0.000 abstract description 3
- 229910052727 yttrium Inorganic materials 0.000 abstract description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 2
- 150000002739 metals Chemical class 0.000 abstract 2
- GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 abstract 1
- 229910001463 metal phosphate Inorganic materials 0.000 abstract 1
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 89
- 229910052760 oxygen Inorganic materials 0.000 description 59
- NZPIUJUFIFZSPW-UHFFFAOYSA-H lanthanum carbonate Chemical compound [La+3].[La+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O NZPIUJUFIFZSPW-UHFFFAOYSA-H 0.000 description 49
- 239000000047 product Substances 0.000 description 49
- 239000001301 oxygen Substances 0.000 description 43
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 40
- 238000006243 chemical reaction Methods 0.000 description 31
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 25
- 239000013067 intermediate product Substances 0.000 description 25
- 229910052698 phosphorus Inorganic materials 0.000 description 23
- 150000002604 lanthanum compounds Chemical class 0.000 description 22
- ICAKDTKJOYSXGC-UHFFFAOYSA-K lanthanum(iii) chloride Chemical compound Cl[La](Cl)Cl ICAKDTKJOYSXGC-UHFFFAOYSA-K 0.000 description 22
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 21
- 239000013078 crystal Substances 0.000 description 21
- 239000011574 phosphorus Substances 0.000 description 21
- 238000001704 evaporation Methods 0.000 description 19
- 230000008020 evaporation Effects 0.000 description 19
- 239000007788 liquid Substances 0.000 description 19
- 239000000843 powder Substances 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 18
- 235000017550 sodium carbonate Nutrition 0.000 description 14
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 13
- WVFDFRMEPUYSCI-UHFFFAOYSA-M Cl[La] Chemical group Cl[La] WVFDFRMEPUYSCI-UHFFFAOYSA-M 0.000 description 13
- 230000017531 blood circulation Effects 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 238000001035 drying Methods 0.000 description 12
- 230000009257 reactivity Effects 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 11
- 210000002700 urine Anatomy 0.000 description 11
- 229910010413 TiO 2 Inorganic materials 0.000 description 10
- 239000012065 filter cake Substances 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- JKSVDWSKYFEURH-UHFFFAOYSA-N carbonic acid;lanthanum Chemical compound [La].OC(O)=O JKSVDWSKYFEURH-UHFFFAOYSA-N 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000001354 calcination Methods 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 230000036571 hydration Effects 0.000 description 8
- 238000006703 hydration reaction Methods 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 238000002441 X-ray diffraction Methods 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 210000000936 intestine Anatomy 0.000 description 7
- JLRJWBUSTKIQQH-UHFFFAOYSA-K lanthanum(3+);triacetate Chemical compound [La+3].CC([O-])=O.CC([O-])=O.CC([O-])=O JLRJWBUSTKIQQH-UHFFFAOYSA-K 0.000 description 7
- 238000005507 spraying Methods 0.000 description 7
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 6
- 229910052785 arsenic Inorganic materials 0.000 description 6
- 238000000502 dialysis Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 235000012054 meals Nutrition 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 5
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- MRELNEQAGSRDBK-UHFFFAOYSA-N lanthanum(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[La+3].[La+3] MRELNEQAGSRDBK-UHFFFAOYSA-N 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- 235000010755 mineral Nutrition 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000011669 selenium Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 229910052711 selenium Inorganic materials 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000010936 titanium Substances 0.000 description 4
- 238000004438 BET method Methods 0.000 description 3
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 229910052787 antimony Inorganic materials 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- XFVGXQSSXWIWIO-UHFFFAOYSA-N chloro hypochlorite;titanium Chemical compound [Ti].ClOCl XFVGXQSSXWIWIO-UHFFFAOYSA-N 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- GAYSPCNXZCAPHX-UHFFFAOYSA-H lanthanum(3+);tricarbonate;octahydrate Chemical compound O.O.O.O.O.O.O.O.[La+3].[La+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O GAYSPCNXZCAPHX-UHFFFAOYSA-H 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 3
- ZCZVZQYXVCHEKH-UHFFFAOYSA-N [O].OC(O)=O Chemical compound [O].OC(O)=O ZCZVZQYXVCHEKH-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- LQFNMFDUAPEJRY-UHFFFAOYSA-K lanthanum(3+);phosphate Chemical compound [La+3].[O-]P([O-])([O-])=O LQFNMFDUAPEJRY-UHFFFAOYSA-K 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000001175 peptic effect Effects 0.000 description 2
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000007669 thermal treatment Methods 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical group [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000006996 Aryldialkylphosphatase Human genes 0.000 description 1
- 108010008184 Aryldialkylphosphatase Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- OPLYJBURBHOMOC-UHFFFAOYSA-N acetic acid;lanthanum Chemical compound [La].CC(O)=O OPLYJBURBHOMOC-UHFFFAOYSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- LULLIKNODDLMDQ-UHFFFAOYSA-N arsenic(3+) Chemical compound [As+3] LULLIKNODDLMDQ-UHFFFAOYSA-N 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- 229910052790 beryllium Inorganic materials 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- JYYOBHFYCIDXHH-UHFFFAOYSA-N carbonic acid;hydrate Chemical compound O.OC(O)=O JYYOBHFYCIDXHH-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 235000021463 dry cake Nutrition 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000001095 inductively coupled plasma mass spectrometry Methods 0.000 description 1
- 229910000765 intermetallic Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229940116314 ketaject Drugs 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- AFCUGQOTNCVYSW-UHFFFAOYSA-H lanthanum(3+);tricarbonate;hydrate Chemical class O.[La+3].[La+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O AFCUGQOTNCVYSW-UHFFFAOYSA-H 0.000 description 1
- 229910052745 lead Inorganic materials 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 238000013059 nephrectomy Methods 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000010242 retro-orbital bleeding Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 125000003748 selenium group Chemical group *[Se]* 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003609 titanium compounds Chemical class 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Abstract
Description
样品 | 化合物 | 与制造方法相对应的例子号 | BET表面积m<sup>2</sup>/g | 10分钟后剩余的PO<sub>4</sub>分数 | 初始一级速率常数K<sub>1</sub>(min<sup>-1</sup>) |
12345678910 | La<sub>2</sub>O(CO<sub>3</sub>)<sub>2</sub>·xH<sub>2</sub>OLa<sub>2</sub>O(CO<sub>3</sub>)<sub>2</sub>·xH<sub>2</sub>OLa<sub>2</sub>O(CO<sub>3</sub>)<sub>2</sub>·xH<sub>2</sub>OLa<sub>2</sub>CO<sub>5</sub>(4h研磨)La<sub>2</sub>O<sub>2</sub>C0<sub>3</sub>La<sub>2</sub>CO<sub>5</sub>(2h研磨)La<sub>2</sub>O<sub>2</sub>CO<sub>3</sub>La<sub>2</sub>CO<sub>5</sub>(无研磨)La<sub>2</sub>(CO<sub>3</sub>)<sub>3</sub>·4H<sub>2</sub>OLa<sub>2</sub>(CO<sub>3</sub>)<sub>3</sub>·1H<sub>2</sub>O | 11111175775工业样品工业 | 41.335.938.825.61818.816.511.94.32.9 | 0.1300.1530.1710.2750.2780.3080.3270.4830.6230.790 | 0.9490.9290.8370.5450.4830.3910.360.4340.1960.094 |
含氧碳酸镧化合物 | 中间磷/肌酸酐比例(与配药前相比减少的%) | 第10和第90百分位 |
A | 48.4% | 22.6-84.4% |
B | 37.0% | -4.1-63.1% |
被测的含氧碳酸La化合物 | 曲线<sub>0-72b</sub>下的平均(sd)面积(ng.h/ml)(标准偏差) | 最大浓度C<sub>max</sub>(ng/ml);(标准偏差) |
A | 54.6(28.0) | 2.77(2.1) |
B | 42.7(34.8) | 2.45(2.2) |
组别ID | 处理 | 实验项 | Sigmacell纤维素 | Teklad膳食 |
I | 负控制 | 0.0% | 1.2% | 98.8% |
II | 化合物B-中水平 | 0.3% | 0.9% | 98.8% |
III | 化合物B-高水平 | 0.6% | 0.6% | 98.8% |
IV | 化合物C-中水平 | 0.3% | 0.9% | 98.8% |
V | 化合物C-高水平 | 0.6% | 0.6% | 98.8% |
尿磷酸盐排泄量(mg/天) | |
对比 | 4.3 |
化合物B=La<sub>2</sub>0<sub>2</sub>CO<sub>3</sub> | 2.3 |
化合物C=La<sub>2</sub>CO<sub>5</sub> | 1.9 |
实验ID | 化合物 | 制备技术 |
1 | La<sub>2</sub>O<sub>3</sub> | 在850摄氏度下将工业(Prochem)La<sub>2</sub>(CO<sub>3</sub>)<sub>3</sub>·H<sub>2</sub>O焙烧16小时 |
2 | La<sub>2</sub>CO<sub>5</sub> | 通过喷雾干燥醋酸镧溶液,并在600摄氏度下焙烧7小时制备(对应于图3的方法) |
3 | LaOCl | 通过喷雾干燥氯化镧溶液,并在700摄氏度下焙烧10小时制备(对应于图1的方法) |
4 | La<sub>2</sub>(CO<sub>3</sub>)<sub>3</sub>·4H<sub>2</sub>O | 由Prochem购买(比较例) |
5 | 碳酸Ti | 通过图11的方法制备,其中LaCl<sub>3</sub>溶液用TiOCl<sub>2</sub>溶液代替。 |
6 | TiO<sub>2</sub> | 利用对应于图2的方法加入氯化钠制备 |
7 | La<sub>2</sub>O(CO<sub>3</sub>)<sub>2</sub>·xH<sub>2</sub>O | 将碳酸钠加到在80摄氏度下的氯化镧溶液中,沉淀(对应于图10的方法) |
8 | La<sub>2</sub>O<sub>2</sub>CO<sub>3</sub> | 将碳酸钠溶液加到在80摄氏度下的氯化镧溶液中,沉淀,然后在500摄氏度下焙烧3小时(图11的方法) |
Claims (12)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40386802P | 2002-08-14 | 2002-08-14 | |
US60/403,868 | 2002-08-14 | ||
US60/430,284 | 2002-12-02 | ||
US60/461,175 | 2003-04-08 | ||
US10/444,774 | 2003-05-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1688511A CN1688511A (zh) | 2005-10-26 |
CN100526219C true CN100526219C (zh) | 2009-08-12 |
Family
ID=35306292
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB03824117XA Expired - Lifetime CN100526219C (zh) | 2002-08-14 | 2003-08-08 | 稀土金属化合物、其制造方法及其使用方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100526219C (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060083791A1 (en) | 2002-05-24 | 2006-04-20 | Moerck Rudi E | Rare earth metal compounds methods of making, and methods of using the same |
CN100398112C (zh) * | 2006-03-24 | 2008-07-02 | 辽宁诺康生物制药有限责任公司 | 一种治疗血磷酸盐过多症的药物及其制备方法 |
WO2011143475A1 (en) * | 2010-05-12 | 2011-11-17 | Spectrum Pharmaceuticals, Inc. | Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use |
EP2855675B1 (en) * | 2012-06-05 | 2017-03-29 | 3M Innovative Properties Company | Lanthanum-based concentration agents for microorganisms |
CN105289521B (zh) * | 2015-10-30 | 2019-03-22 | 无锡市新都环保科技有限公司 | 表面改性松针负载氢氧化镧除磷吸附剂的制备方法 |
CN114524452A (zh) * | 2017-10-30 | 2022-05-24 | 浙江大学 | 一种纳米碳酸镧水合物及其制备方法和应用 |
CN108393077A (zh) * | 2018-03-28 | 2018-08-14 | 杨帮燕 | 一种高效率吸附型除磷剂的制备方法 |
WO2020085438A1 (ja) * | 2018-10-24 | 2020-04-30 | 三井金属鉱業株式会社 | 吸着材およびその製造方法、並びに吸着成形体 |
CN111393875A (zh) * | 2020-03-30 | 2020-07-10 | 内蒙古航天红峡化工有限公司 | 一种二氧化钛包覆稀土基珠光颜料的制备方法 |
CN114577782B (zh) * | 2020-12-01 | 2023-07-25 | 四川大学 | 一种比率型催化发光检测有机胺的方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3922331A (en) * | 1973-11-14 | 1975-11-25 | Us Interior | Preparation of microporous rare-earth oxyhalides |
US4462970A (en) * | 1981-08-19 | 1984-07-31 | Hughes Aircraft Company | Process for preparation of water-free oxychloride material |
US4929787A (en) * | 1987-08-05 | 1990-05-29 | Institut Francais Du Petrole | Process for converting methane to higher hydrocarbons |
CN1184428A (zh) * | 1995-03-25 | 1998-06-10 | 约翰逊马西有限公司 | 含有选择的碳酸镧水合物的药物组合物 |
CN1270526A (zh) * | 1997-09-19 | 2000-10-18 | 克罗斯菲尔德有限公司 | 作为磷酸盐结合剂的混合或硫酸化的金属化合物 |
-
2003
- 2003-08-08 CN CNB03824117XA patent/CN100526219C/zh not_active Expired - Lifetime
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3922331A (en) * | 1973-11-14 | 1975-11-25 | Us Interior | Preparation of microporous rare-earth oxyhalides |
US4462970A (en) * | 1981-08-19 | 1984-07-31 | Hughes Aircraft Company | Process for preparation of water-free oxychloride material |
US4929787A (en) * | 1987-08-05 | 1990-05-29 | Institut Francais Du Petrole | Process for converting methane to higher hydrocarbons |
CN1184428A (zh) * | 1995-03-25 | 1998-06-10 | 约翰逊马西有限公司 | 含有选择的碳酸镧水合物的药物组合物 |
CN1270526A (zh) * | 1997-09-19 | 2000-10-18 | 克罗斯菲尔德有限公司 | 作为磷酸盐结合剂的混合或硫酸化的金属化合物 |
Also Published As
Publication number | Publication date |
---|---|
CN1688511A (zh) | 2005-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7588782B2 (en) | Rare earth metal compositions for treating hyperphosphatemia and related methods | |
US8852543B2 (en) | Rare earth metal compounds, methods of making, and methods of using the same | |
CN102498068B (zh) | 方法 | |
CN100526219C (zh) | 稀土金属化合物、其制造方法及其使用方法 | |
CN101115490B (zh) | 药物活性化合物、它们的制备方法、包含它们的组合物及它们的应用 | |
AU2003298800B2 (en) | Rare earth compositions and structures for removing phosphates from water | |
CN101827602A (zh) | 用于治疗高磷酸盐血症的混合金属化合物 | |
EP1647524A2 (en) | Rare earth metal compounds, methods of making, and methods of using the same | |
ES2907070T3 (es) | Compuestos de metales de tierras raras, métodos de fabricación y métodos de uso de los mismos | |
TWI655948B (zh) | 用於高血鉀治療之微孔矽酸鋯 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1082242 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1082242 Country of ref document: HK |
|
C56 | Change in the name or address of the patentee |
Owner name: GUANGPU PHARMACEUTICAL CO. Free format text: FORMER NAME: ALTAIRNANO INC. |
|
CP03 | Change of name, title or address |
Address after: American California Patentee after: Spectrum pharmaceuticals Address before: Nevada Patentee before: ALTAIRNANO, Inc. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20210924 Address after: California, USA Patentee after: Unisexivir treatment Co. Address before: California, USA Patentee before: Spectrum pharmaceuticals |
|
TR01 | Transfer of patent right | ||
CX01 | Expiry of patent term |
Granted publication date: 20090812 |
|
CX01 | Expiry of patent term |